Contact:
Robert Gottlieb
RMG Associates, LLC
857-891-9091
Robertmg52@gmail.com

Cellanyx Diagnostics' Live Tumor Cell Phenotypic Risk Stratification Test Data from 'Normal' Tissue Samples Recognized at AdMeTech Foundation's First Global Summit on Precision Diagnosis for Prostate Cancer with Second Place in Poster Competition

Beverly, MA, September 28, 2016 – Cellanyx Diagnostics' live tumor cell phenotypic test data demonstrating the potential to stratify prostate cancer risk from 'normal' [field] tissue samples taken away from the tumor, was awarded second place in the poster competition at the AdMeTech Foundation's First Global Summit on Precision Diagnosis for Prostate Cancer, Sept. 16-18. The citation, along with Cellanyx's recent award for the best prostate cancer biomarker poster at the annual meeting of American Urological Association Annual meeting, underscores growing recognition of the potential for the company's live tumor cell phenotypic tests. Cellanyx is developing the prostate cancer phenotypic test to provide a quantitative assessment of the potential for tumor aggressiveness and/or metastasis, thus predicting the potential for adverse pathology. Cellanyx's test complements the standard-of-care Gleason pathology scores to allow improved risk-stratification of patients.

Biopsies to detect prostate cancer only sample a small quantity [~one percent] of prostate tissue, and as a result, standard pathology tests may miss the potential cancer at the time of initial biopsy. This inference is supported by the fact that an estimated 80 percent of repeat prostate cancer biopsies are positive.

Cellanyx presented data from 60 prostate tissue samples taken at the time of radical prostatectomy from 'normal' tissue adjacent to the suspected tumor tissue (referred to as 'field tissue' samples). The samples were part of larger blinded clinical validation study involving 250 prostate cancer patients and field tissue samples were collected from these radical prostatectomy patients (at the time of surgery).

Compared with currently available pathology and other diagnostic tests, the Cellanyx test predicted the adverse pathology potential from both, the field and tumor samples, with greater than 85 percent sensitivity and specificity. The test also predicted the

likelihood of locally aggressive and metastatic pathologies with higher accuracy as evaluated by Receiver Operator Curves (ROC) by Area Under the Curve (AUC) measurements. Based on these results, Cellanyx plans to conduct a prospective, clinical utility study in patients undergoing needle biopsies to compare its predictive metrics to the pathology found in study patients who subsequently undergo radical prostatectomy.

The poster is entitled, "Analytical Validation of a Live-Cell Phenotypic Biomarker-Based Diagnostic Assay for the Prediction of Adverse Pathology in Prostate Cancer from Field Biopsy Cores." Click hyperlinked text to view the poster or the abstract.

About Cellanyx Diagnostics

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company's unique 'biopsy-on-a-chip' methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

###